Background/aim: The Archer FusionPlex platform is widely used for comprehensive fusion-gene detection in cancer tissues. This platform separately displays results for strong-evidence and weak-evidence fusion candidates (WEFCs). Distinctive fusion patterns are frequently found in the weak-evidence category and information about the patterns is clinically essential.
Patients and methods: We describe the type and frequency of WEFCs observed using the FusionPlex Sarcoma Panel (S Panel) and the FusionPlex ALK, RET, and ROS1 ver2 Panel (ARR Panel).
Results: A total of 97 specimens were examined and 620 candidates were detected and categorized as WEFCs. A median of five WEFCs were detected per sample. In the S Panel group, there were 13 WEFCs with a frequency of more than 1%. In the ARR Panel group, a total of 16 WEFCs were detected with a frequency of more than 1%.
Conclusion: Specific WEFCs were detected according to the panel selected.
Keywords: FusionPlex; Ion Torrent; Next-generation sequencing; fusion gene; non-small cell lung cancer; sarcoma.
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.